We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+21.78%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$18.7M
Cap. Flow
-$2.45M
Cap. Flow %
-1.53%
Top 10 Hldgs %
58.41%
Holding
38
New
11
Increased
7
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
WBA
Walgreens Boots Alliance
WBA
+$7.55M
2
NKTR icon
Nektar Therapeutics
NKTR
+$7.49M
3
BKD icon
Brookdale Senior Living
BKD
+$7.1M
4
HCA icon
HCA Healthcare
HCA
+$6.67M
5
BSX icon
Boston Scientific
BSX
+$4.81M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$10.6M
2
HOLX
Hologic
HOLX
+$9.23M
3
BIO icon
Bio-Rad Laboratories Class A
BIO
+$8.93M
4
NXTM
NxStage Medical Inc.
NXTM
+$7.12M
5
AMGN icon
Amgen
AMGN
+$5.13M

Sector Composition

Rank Sector Weight
1 Healthcare 95.85%
2 Industrials 4.15%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
$12.2M 7.64%
965,000
+200,000
+26% +$2.37M
PCRX icon
2
Pacira BioSciences
PCRX
$1.05B
$12.1M 7.55%
265,000
-8,000
-3% -$346K
NKTR icon
3
Nektar Therapeutics
NKTR
$2.53B
$11.7M 7.33%
+33,333
New +$7.49M
GILD icon
4
Gilead Sciences
GILD
$187B
$10.2M 6.37%
150,000
+50,000
+50% +$3.52M
SPNC
5
DELISTED
Spectranetics Corp
SPNC
$8.74M 5.46%
300,000
-29,600
-9% -$789K
JAZZ icon
6
Jazz Pharmaceuticals
JAZZ
$16B
$8.27M 5.17%
57,000
-20,000
-26% -$2.6M
NVCR icon
7
NovoCure
NVCR
$2.09B
$8.03M 5.01%
990,750
+165,750
+20% +$1.2M
TDOC icon
8
Teladoc Health
TDOC
$1.14B
$7.63M 4.76%
305,000
-110,600
-27% -$2.3M
WBA
9
DELISTED
Walgreens Boots Alliance
WBA
$7.47M 4.67%
+90,000
New +$7.55M
HCA icon
10
HCA Healthcare
HCA
$87.7B
$7.12M 4.45%
+80,000
New +$6.67M
LH icon
11
Labcorp
LH
$26.5B
$6.89M 4.3%
55,872
-3,492
-6% -$413K
STE icon
12
Steris
STE
$21.9B
$6.82M 4.26%
98,150
+35,150
+56% +$2.43M
BKD icon
13
Brookdale Senior Living
BKD
$2.81B
$6.8M 4.25%
+503,000
New +$7.1M
HIND
14
Vyome Holdings
HIND
$15.6M
– –
0
– –
CORV
15
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$5.49M 3.43%
1,825,000
– –
BSX icon
16
Boston Scientific
BSX
$69.3B
$4.97M 3.11%
200,000
+197,800
+8,991% +$4.81M
ALKS icon
17
Alkermes
ALKS
$7.73B
$4.68M 2.92%
80,000
+2,000
+3% +$113K
CORI
18
DELISTED
Corium International, Inc.
CORI
$4.44M 2.78%
1,063,000
+325,758
+44% +$1.2M
LNTH icon
19
Lantheus
LNTH
$6.59B
$3.63M 2.27%
+290,700
New +$3.08M
ATHN
20
DELISTED
Athenahealth, Inc.
ATHN
$3.38M 2.11%
30,000
-11,000
-27% -$1.28M
NXTM
21
DELISTED
NxStage Medical Inc.
NXTM
$2.95M 1.84%
110,000
-257,690
-70% -$7.12M
SRCL
22
DELISTED
Stericycle Inc
SRCL
$2.47M 1.54%
+29,800
New +$2.39M
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.72M 1.08%
+471,149
New +$1.99M
AKRX
24
DELISTED
Akorn Inc
AKRX
$1.71M 1.07%
+70,969
New +$1.54M
NVRO
25
DELISTED
NEVRO CORP.
NVRO
$1.6M 1%
+17,100
New +$1.55M
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q1 2017 Portfolio in Review

As of Q1 2017, Tamarack Advisers held 38 positions worth $160M, up 13% from $141M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Tamarack Advisers's Q1 2017 filing shows 11 new, 7 increased, 9 reduced and 8 closed positions. Its largest new stake was Walgreens Boots Alliance: 90,000 shares worth $7.47M. The largest sale was Ariad Pharmaceuticals Inc, an estimated $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • Tamarack Advisers's largest Q1 2017 buy was Walgreens Boots Alliance: 90,000 shares worth $7.47M.
  • Tamarack Advisers added most to Boston Scientific in Q1 2017, an estimated $4.81M increase.
  • Tamarack Advisers's biggest Q1 2017 reduction was NxStage Medical Inc., cutting an estimated $7.12M.
  • Tamarack Advisers fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $10.6M.
  • Tamarack Advisers's ten largest holdings make up 58% of its $160M portfolio in Q1 2017.
  • Tamarack Advisers opened 11 new positions and closed 8 in Q1 2017.
  • Tamarack Advisers's portfolio value rose 13% quarter-over-quarter to $160M.

Based on Tamarack Advisers's 13F filing for Q1 2017, filed 12 May 2017.